Apyx Medical Corporation Reports Third Quarter 2025 Financial Results

Initiated full U.S. commercial launch of AYON Body Contouring System™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectationsSubmitted new 510(k) for AYON for device label expansion to include power liposuctionIncreased total revenue guidance for FY2025 to a range of $50.5 million to $52.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader ...